“Compared with 10 years ago, pharmaceutical companies are taking seriously the problems people face in low- and middle-income countries when accessing health care. The situation is still fragile. A retreat by one company, or a drop in health care investments will jeopardize progress made so far.”
Jayasree Iyer, executive director of the Access to Medicines Foundation (AMF), commenting on AMF’s 10-year analysis of how pharma is working to improve access to medicines in the developing world. The analysis finds the issue is now widely seen as being of strategic importance, with 17 out of 20 leading pharma companies having targets for addressing access in low- and middle-income countries. That compares to eight companies that set access-related goals in 2010

“Broadening our platform into biologics has always been key to our strategy. We have finally found the perfect match. Machine learning is not only revolutionizing the world of small molecules, it is also changing the world of big molecules and manufacturing. It will make our offering even stronger than ever before.”
Werner Lanthaler, CEO, Evotec SE, on the decision to acquire Just Biotherapeutics Inc., which has an integrated, flexible biologics platform, based on a proprietary machine learning tool, Abacus, that can predict structures and select optimal molecules

[Inheris Biopharma Inc.] “will lead all of the preparations for the potential commercialization of NKTR-181, as well as development of other CNS programs, enabling Nektar to remain focused on advancing our immuno-oncology and immunology development pipeline.”
Howard Robin, president and CEO, Nektar Therapeutics Inc., on the launch of its subsidiary that will be responsible for the launch and marketing of investigational mu-opioid agonist NKTR-181, targeting chronic back pain drug, once it gains FDA approval